JPWO2022130175A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022130175A5 JPWO2022130175A5 JP2023535824A JP2023535824A JPWO2022130175A5 JP WO2022130175 A5 JPWO2022130175 A5 JP WO2022130175A5 JP 2023535824 A JP2023535824 A JP 2023535824A JP 2023535824 A JP2023535824 A JP 2023535824A JP WO2022130175 A5 JPWO2022130175 A5 JP WO2022130175A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- ceutically acceptable
- linked
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 150000001602 bicycloalkyls Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125671P | 2020-12-15 | 2020-12-15 | |
| US63/125,671 | 2020-12-15 | ||
| PCT/IB2021/061645 WO2022130175A1 (en) | 2020-12-15 | 2021-12-13 | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552862A JP2023552862A (ja) | 2023-12-19 |
| JPWO2022130175A5 true JPWO2022130175A5 (enrdf_load_stackoverflow) | 2024-11-06 |
Family
ID=78957649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535824A Pending JP2023552862A (ja) | 2020-12-15 | 2021-12-13 | ピリド［２，３－ｄ］イミダゾール誘導体、および皮膚疾患の処置のためのｉｔｋの阻害剤としてのそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240124439A1 (enrdf_load_stackoverflow) |
| EP (1) | EP4263538A1 (enrdf_load_stackoverflow) |
| JP (1) | JP2023552862A (enrdf_load_stackoverflow) |
| CA (1) | CA3205023A1 (enrdf_load_stackoverflow) |
| WO (1) | WO2022130175A1 (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024123175A1 (en) | 2022-12-06 | 2024-06-13 | Erasmus University Medical Center Rotterdam | Compositions for treating immune checkpoint blockade therapy resistant cancers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| WO2013026021A2 (en) * | 2011-08-18 | 2013-02-21 | Buck Institute For Research On Aging | Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease |
-
2021
- 2021-12-13 CA CA3205023A patent/CA3205023A1/en active Pending
- 2021-12-13 WO PCT/IB2021/061645 patent/WO2022130175A1/en active Application Filing
- 2021-12-13 EP EP21827674.9A patent/EP4263538A1/en active Pending
- 2021-12-13 US US18/257,195 patent/US20240124439A1/en active Pending
- 2021-12-13 JP JP2023535824A patent/JP2023552862A/ja active Pending